WO1999008540A1 - Produits laitiers a teneur elevee en acides linoleiques conjugues - Google Patents

Produits laitiers a teneur elevee en acides linoleiques conjugues Download PDF

Info

Publication number
WO1999008540A1
WO1999008540A1 PCT/US1998/016829 US9816829W WO9908540A1 WO 1999008540 A1 WO1999008540 A1 WO 1999008540A1 US 9816829 W US9816829 W US 9816829W WO 9908540 A1 WO9908540 A1 WO 9908540A1
Authority
WO
WIPO (PCT)
Prior art keywords
milk
fatty acid
fat
dairy product
cla
Prior art date
Application number
PCT/US1998/016829
Other languages
English (en)
Inventor
Sharon T. Franklin
Robert J. Baer
David J. Schingoethe
Original Assignee
South Dakota State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South Dakota State University filed Critical South Dakota State University
Priority to NZ503398A priority Critical patent/NZ503398A/en
Priority to AU88287/98A priority patent/AU728842B2/en
Priority to EP98939938A priority patent/EP1005277A4/fr
Publication of WO1999008540A1 publication Critical patent/WO1999008540A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants

Definitions

  • CLA Conjugated linoleic acids
  • Conjugated linoleic acids are found primarily in meat (Ha et al., Carcinogenesis, 8:1881 (1987); Pariza et al., Carcinogenesis, 6:591 (1985)) and dairy products from ruminant animals (Ha et al., J. Agric. Food Chem., 37:75 (1989); Lin et al., J. Dairy Sci., 78:2358 (1995)).
  • the collective term, CLA incorporates several isomers, with double bonds present at positions 9 and 11, or 10 and 12, or 11 and 13 on the carbon chain of octadecadienoic acid. The double bond at each of the positions can be in the cis- or trans- form (Parodi, Aust.
  • mice fed a diet containing a synthetic form of CLA and subjected to cancer initiation treatments developed 50% fewer forestomach tumors than mice fed control diets (Ha et al., Cancer Res., 50, 1097 (1990)).
  • Rats fed diets supplemented with 0.5, 1, or 1.5% synthetic CLA and subjected to carcinogens developed 32, 56, and 60%) fewer mammary adenocarcinomas, respectively, than rats fed control diets (Ip et al., Cancer Res., 5J_, 6118 (1991)).
  • Dairy products are an important source in human diets of naturally occuring CLA. Dairy products typically contain from 2.5 to 7.0 mg CLA g of fat (Lin et al., J. Dairy Sci., 78:2358 (1995)). Research reported by Riel indicated the total conjugated diene content of milk fat can vary from 0.78 to 1.46%o (or approximately 8 to 15 mg/g) of fat depending on season (J. Dairy Sci., 46:102 (1963)). Riel found that cows consuming pasture during the spring have increased amounts (to 1.46%>) of conjugated dienoic acid in the milk fat. In contrast, however, Mackle et al. (J. Dairy Sci., 80 (Suppl.
  • Ruminal biohydrogenation of dietary long-chain fatty acids also may result in production of trans C18:l fatty acids which can be incorporated in milk fat (see, e.g., Loor et al., J. Dairy Sci., 80(Suppl. 1):164 (1997); Piperova et al., J. Dairy Sci., 80(Suppl. 1):164 (1997); Wonsil et al., J. Nutr., 124:556 (1994)).
  • Dairy products typically contain low concentrations of trans C18:l fatty acids, therefore, few studies have investigated specific trans C18:l fatty acids.
  • Transvaccenic acid [trans 18:l(n-7)] has been shown to inhibit growth of colonic cancer cells in vitro (A wad et al., Cancer Letters, 91:55 (1995)) and decrease fat accumulation in rat adipocytes (Cromer et al., J. Nutr., 125:2394 (1995)). Increased transvaccenic acid in dairy products may have important health benefits for humans.
  • Another C18:l fatty acid, petroselinic acid may also be a beneficial fatty acid in human diets.
  • Petroselenic acid [18:l(n-12)] has been shown to decrease the concentration of arachidonic acid in lipids from heart, liver, and blood (Weber et al, J.
  • Omega-3 fatty acids also have been shown to provide important health benefits.
  • Two omega-3 fatty acids, eicosapentaenoic acid (“EPA”, C20:5) and docosahexaenoic acid (“DHA”, C22:6) have been shown to have beneficial effects on human cardiovascular disease (see, e.g., Bang et al., Acta Med. Scand., 200:69 (1976); Hirai et al., Lancet, 2(8204):! 132-33 (1976)), rheumatoid arthritis (Kremer et al, Ann. Intern.
  • omega- 3 fatty acids intake of omega- 3 fatty acids has been linked to inhibition of prostate cancer (Rose et al., Lipids, 27:798 (1992)) and pancreatic cancer (Roebuck, Lipids, 27:804 (1992)).
  • Human dietary sources of long-chain omega-3 fatty acids are generally limited to some cold water, deep sea fish and a few plant sources. Incorporation of omega-3 fatty acids into a widely available and palatable form of food, such as dairy products, would provide greater access to omega-3 fatty acids at a reasonable price.
  • the fat fraction of milk from ruminant animals contains numerous fatty acids, mainly saturated (circa 66%), but also monounsaturated (circa 30%>) and polyunsaturated (circa 4%>). All short-chain (C4:0 to C10:0) and half of the medium-chain (C12:0 to C17:0) fatty acids in milk fat are synthesized from acetate and ⁇ -hydroxybutyrate in the mammary gland epithelial cells. The other half of medium-chain and almost all long-chain (C18:0 and longer) fatty acids are derived from blood plasma fatty acids of dietary origin as modified by rumen microbial fermentation or from mobilization of body fat stores.
  • the invention relates to dairy products enriched in conjugated linoleic acids ("CLA") and other beneficial unsaturated fatty acids.
  • the dairy product typically has a fat fraction with a fatty acid composition which includes at least about 15 mg/g CLA, as well as other beneficial fatty acids such as transvaccenic acid, petroselinic acid and omega-3 fatty acid(s).
  • Milk with this unsaturated fatty acid content may be produced by a ruminant which has been fed a diet which includes a fish-derived product such as fish oil or fish meal.
  • the diet typically includes about 0.25%) to about 10%) by dry weight of oil supplied by the fish-derived product.
  • the ruminant is an animal such as a cow, sheep, buffalo or goat.
  • dairy products of the present invention include milk in raw or processed form and other products derived from the milk.
  • the processed milk may be in a variety of forms, e.g., reduced and low fat forms, such as "1% milk,” or enriched fat forms, such as cream or "half and half.”
  • Other examples of the present dairy products include products obtained by further processing of the milk, such as natural and processed cheeses, cottage cheese, yogurt, butter, ice cream, butter milk, cultured butter milk, sour cream, ghee, frozen yogurt, sherbet, anhydrous butter oil, anhydrous butter fat, powdered milk, condensed milk, evaporated milk and whey products.
  • the unsaturated fatty acid-enriched milk may be produced by feeding a lactating ruminant animal a diet which includes fish oil at about 0.5%> to about 5%> by dry weight of the total diet. Typically, the diet is supplemented with about 1% to about 4%> by dry weight fish oil.
  • milk is collected from the ruminant fed the fish-derived product. The milk can be used as collected ("raw milk") or may be further processed into another dairy product using standard methods.
  • the milk or other dairy product produced by the method of the invention has an enhanced level of CLA relative to milk produced by ruminants fed a diet not supplemented with such an oil source.
  • the dairy product includes a fat fraction with a fatty acid composition which includes at least about 20 mg/g and more preferably, at least about 25 mg/g CLA.
  • the dairy product has a fat fraction which contains enhanced levels of unsaturated fatty acids such as omega-3 fatty acid(s), transvacennic acid, and/or petroselinic acid.
  • the present invention also provides isolated lipid fractions and fatty acid compositions derived from the unsaturated fatty acid-enriched raw milk.
  • the lipid portion can be separated from the raw milk using conventional methods, e.g., supercritical fluid extraction or extraction with organic solvent.
  • the lipid composition obtained in this manner typically has a fatty acid composition which includes at least about 20 mg/g CLA and at least about 10 mg/g omega-3 fatty acid(s). Substantial amounts of triglycerides including transvaccenic acid and petroselinic acid esters are also generally present.
  • the lipid composition derived from the raw milk may be hydrolysed to convert the triglycerides to free fatty acids or simple corresponding esters (e.g., "lower alkyl” esters - (C(l)-C(6) alkyl esters) of the fatty acids.
  • the triglycerides may be initially converted to free fatty acids which are subsequently esterified.
  • the products of the hydrolysis reaction may be isolated in free acid form or as a salt of the fatty acid(s).
  • the fatty acid salt(s) generally include one or more water soluble monovalent cations as the counterion, e.g., potassium (K + ), sodium (Na + ) and/or ammonium (NH/).
  • K + potassium
  • Na + sodium
  • NH/ ammonium
  • Either the lipid composition or the isolated fatty acids (or their corresponding esters) may be further processed to obtain various fractions based on boiling point, melting point, solubility, fractional crystallization or other similar properties.
  • airy product includes milk in raw and processed form, natural and processed cheeses, cottage cheese, yogurt, butter, ice cream, butter milk, cultured butter milk, sour cream, ghee, frozen yogurt, sherbet, anhydrous butter oil, anyhdrous butter fat, powdered milk, condensed milk, evaporated milk, whey products and other milk-based products.
  • the term “dairy product” includes any of the above product having at least about 0.5 wt.%> fat content.
  • raw milk and "milk produced by a ruminant animal” means isolated milk in the form directly produced by the ruminant without any further processing.
  • milk product means any product having a fat content of at least about 0.5 wt. %> derived from the raw milk by a process which does not alter its liquid state or substantially change the fatty acid composition of the fat fraction.
  • milk product includes both raw milk as well as milk which has been processed to enhance its shelf life (e.g., via pasteurization), to alter its physical consistency (e.g., via homogenization), and/or to alter the overall fat content (e.g., via separation).
  • milk products having an altered overall fat content include enriched fat, full fat, low fat milk (e.g., 1%> milk), reduced fat (e.g., 2%> milk), half and half, and cream, as well as flavored milk products.
  • a fatty acid is an aliphatic (saturated or unsaturated) monocarboxylic acid.
  • Lipids are understood to be fats or oils including the glyceride esters of fatty acids along with associated phosphatides, sterols, and related compounds.
  • a commonly employed shorthand system is used in this specification to denote the structure of the fatty acids. This system uses the letter "C” accompanied by a number denoting the number of carbons in the hydrocarbon chain, followed by a colon and a number indicating the number of double bonds,e.g., C20:5, eicosapentaenoic acid. Fatty acids are numbered starting at the carboxy carbon.
  • the position of the double bonds may be indicated by adding the Greek letter delta ( ⁇ ) followed by the carbon number of the double bond; e.g., C20:5omega-3 ⁇ 5 ' 8 ' ! 1,14 ' 17 .
  • the "omega” notation is a shorthand system for unsaturated fatty acids whereby numbering from the CH 3 - terminal carbon is used.
  • w3 may be used to symbolize “omega-3,” when using the numeral shorthand nomenclature described herein.
  • Omega-3 highly unsaturated fatty acids are understood to be polyethylenically unsaturated fatty acids in which the last ethylenic bond is between the third and fourth carbons from the CH 3 end of the fatty acid.
  • Eicosapentaenoic acid is then designated C20:5w3 (also referred to herein as "C20:5"), docosapentaenoic acid (C22:5 ⁇ 7 ' 11>13 ' 16 ' 19 ) is C22:5w3 (also referred to herein as "C22:5"), and docosahexaenoic acid (C22:6 ⁇ 4 ' i3 ' 16 - 19 ) is C22:6w3 (also referred to herein as "C22:6").
  • HUFA highly unsaturated fatty acid
  • conjugated linoleic acid or “CLA” means a fatty acid that is an octadecadienoic acid having conjugated double bonds at positions 9 and 11, 10 and 12, or 11 and 13 on the carbon chain of linoleic acid, wherein the double bond at each of these positions can be in either the cis or trans configuration.
  • CLA refers to a fatty acid composition made up of one or more of the "conjugated linoleic acid” isomers.
  • omega-3 fatty acid refers to a fatty acid having a double bond between the third and fourth carbons from the end of the aliphatic chain of the fatty acid.
  • omega-3 fatty acids include ⁇ -linolenic (“C18:3 ⁇ ”), eicosapentaenoic acid (a C20:5 fatty acid) and docosahexaenoic acid (“DHA”; a C22:6 fatty acid).
  • ruminant includes a cow, goat, sheep, buffalo, deer or other member of the Ruminantia suborder of hooved mammals.
  • Fat is made up of triacylglycerol molecules (sometimes termed triglycerides).
  • triacylglycerols comprise three long fatty acid chains esterified to glycerol; or, alternatively phrased, glycerol esterified by addition thereto of three long chain fatty acids.
  • the terms "triacylglycerols” and “triglycerides” are intended to be interchangeable.
  • fats and oils derived from any given plant or animal source comprise a mixture of triacylglycerols, characteristic of the specific source.
  • the mixture of fatty acids isolated from complete hydrolysis of the triacylglycerols in a specific fat or oil are generally referred to as a "fatty acid composition".
  • fatty acid composition reference is made to the identifiable fatty acid residues in the various triacylglycerols.
  • the distribution of specific identifiable fatty acids is typically characterized by the amounts of the individual fatty acids relative to the total mixture of fatty acids obtained from hydrolysis of the particular oil stock.
  • the amount of an individual fatty acid * is stated as the amount in milligrams (mg) of the butyl ester of the specified fatty acid relative to the total weight in grams (g) of the butyl esters of all the fatty acids in the fatty acid composition.
  • the amount of a fatty acid may be stated as mg of the fatty acid per gram of total fat.
  • Typical fatty acid compositions of fish oil are as shown in Table 1 below.
  • the generic fish oil shown in Table 1 was purchased from a pharmacy; the Menhaden fish oil was obtained from Zapata Protein, Inc. (Reedville, NA).
  • Palmitic (C16:0) and stearic (C18:0) acids are saturated fatty acids and triacylglycerol acyl chains formed by the esterification of either of these acids do not contain any double carbon-carbon bonds.
  • many fatty acids such as oleic acid (a C 18 : 1 fatty acid), linoleic acid (a C 18 :2 fatty acid), and linolenic acid (a
  • Oleic acid is an 18 carbon fatty acid with a single double bond
  • linoleic acid is an 18 carbon fatty acid with two double bonds or points of unsaturation
  • linolenic is an 18 carbon fatty acid with three double bonds.
  • oleic acid is (Z)-9-octadecanoic acid
  • linoleic acid is (Z,Z)-9,12-octadecadienoic acid
  • ⁇ -linolenic acid is (Z,Z,Z)-9,12,15-octadecatrienoic acid (C18:3 ⁇ )
  • ⁇ -linolenic acid is the (Z,Z,Z)-6,9,12 isomer of octadecatrienoic acid
  • the present dairy products typically also contain other unsaturated fatty acids such as transvaccenic acid, petroselenic acid and/or other omega-3 fatty acid(s).
  • the invention provides a dairy product enriched in one or more conjugated linoleic acids (collectively refered to as "CLA") and/or other beneficial unsaturated fatty acids.
  • the dairy product typically has a fat fraction with a fatty acid composition which includes at least about 15 mg/g CLA.
  • the CLA content of the dairy product is at least about 20 mg/gram of fat and, more preferably, at least about 25 mg/gram of fat.
  • the dairy product may be produced by a ruminant which has been fed a diet * which includes a fish-derived product such as fish oil or fish meal.
  • the diet comprises no more than about 10%> by dry weight and more preferably less than about 5% by dry weight of oil supplied by the fish-derived product.
  • the diet comprises about 1% to about 4%> by dry weight of a fish oil.
  • fish oil include, but are not limited to, Menhaden fish oil, cod liver oil, mackerel oil, salmon oil, catfish oil, herring oil, sardine oil or whale oil.
  • the ruminant is an animal such as a cow, sheep, buffalo, deer or goat.
  • the ruminant is typically fed the diet including a fish-derived product for at least about two days and, preferably, for at least about one week prior to collection of the milk produced.
  • milk produced by a ruminant fed a diet including a fish-derived product such as fish oil may also be enriched in omega-3 fatty acids, such as ⁇ -linolenic acid (C18:3 ⁇ ), eicosapentaenoic acid (“EPA”; C20:5) and docosahexaenoic acid (“DHA”; C22:6).
  • omega-3 fatty acids such as ⁇ -linolenic acid (C18:3 ⁇ ), eicosapentaenoic acid (“EPA”; C20:5) and docosahexaenoic acid (“DHA”; C22:6).
  • the milk typically has a fatty acid composition which includes at least about 10 mg/g omega-3 fatty acid(s).
  • the omega-3 fatty acid composition includes at least about 8 mg/g ⁇ - linolenic acid, at least about 2 mg/g eicosapentaenoic acid, and/or at least about 0.5 mg/g docosahexaenoic acid. More preferably, the omega-3 fatty acid composition includes at least about 12 mg/g ⁇ -linolenic acid, at least about 4 mg/g eicosapentaenoic acid, at least about 0.8 mg/g docosahexaenoic acid or any combination thereof.
  • the dairy product of the invention can be enriched in other fatty acids such as C18:3 ⁇ , transvaccenic acid and/or petroselinic acid.
  • the fatty acid composition includes at least about 3 mg/g C18:3 ⁇ , at least about 25 mg/g transvaccenic acid, at least about 8 mg/g petroselinic acid, or any combination thereof.
  • the fatty acid composition includes at least about 50 mg/g transvaccenic acid together with a variety of other unsaturated fatty acids.
  • dairy products of the present invention include milk in raw or processed form and other products derived from the milk.
  • the milk may be processed into a variety of forms, e.g., reduced fat such as "2%> milk” or enriched fat forms such as cream and "half and half.”
  • Other examples of the present dairy products include products obtained by further processing of the milk, such as natural * and processed cheeses, cottage cheese, yogurt, butter, ice cream, butter milk, cultured butter milk, sour cream, ghee, frozen yogurt, sherbet, anhydrous butter oil, anyhdrous butter fat, powdered milk, condensed milk, evaporated milk and whey products.
  • the CLA-enriched milk is produced by feeding a lactating ruminant animal a diet which includes a fish-derived product such as fish oil or fish meal.
  • the diet may include fish oil as about 0.25%> to about 10%> by dry weight of the total diet.
  • the diet is supplemented with about 0.5%> to about 5%> by dry weight of the fish oil (as a percentage of the total diet).
  • the fish oil is no more than about 4%> by dry weight of the total diet.
  • milk is collected from the ruminant fed the fish-derived product. The milk can be used as collected, and may be further processed into another dairy product using standard methods.
  • the milk or other dairy product produced by the method of the invention includes an enhanced level of CLA relative to milk produced by ruminants fed a diet not supplemented with an oil source.
  • the CLA content of the dairy product is at least about 20 mg/gram of fat and, more preferably, at least about 25 mg/gram of fat.
  • the ruminant is fed the diet for at least about one week. In another embodiment, the ruminant is fed the diet for at least about one day.
  • ruminants for use in method of the invention include, but are not limited to, a cow, deer, goat, buffalo or sheep.
  • HUFAs Highly unsaturated fatty acids
  • Saturation of omega- 3 HUFAs can be reduced or prevented by the introduction of synthetic antioxidants or naturally occurring antioxidants, such as beta-carotene, vitamin E and vitamin C, into the dairy products.
  • Synthetic antioxidants such as butylated hydroxytoluene (“BHT”), butylated * hydroxyanisole (“BHA”), t-butylhydroquinone (“TBHQ”), and ethoxyquin, or natural antioxidants such as tocopherols, can be incorporated into the dairy products or food or feed products derived therefrom by adding them to the products during processing.
  • BHT butylated hydroxytoluene
  • BHA butylated * hydroxyanisole
  • TBHQ t-butylhydroquinone
  • ethoxyquin ethoxyquin
  • natural antioxidants such as tocopherols
  • Lipids containing the CLA and other beneficial unsaturated fatty acids can also be extracted from the milk products by any suitable means, such as by supercritical fluid extraction, or by extraction with solvents such as chloroform, hexane, methylene chloride, methanol, and the like, and the extract evaporated under reduced pressure to produce a sample of concentrated lipid material.
  • the CLA and other beneficial unsaturated fatty acids in this preparation may be further concentrated by hydrolyzing the lipids and concentrating the unsaturated fraction by employing traditional methods such as urea adduction, fractional distillation or column fractionation.
  • the lipids can also be extracted from the milk products into vegetable or other edible oil.
  • the extracted oils can be refined by well-known processes routinely employed to refine vegetable oils (e.g., chemical refining or physical refining). These refining processes can remove impurities from extracted oils before they are used or sold as edible oils.
  • the refining process consists of a series of processes to degum, bleach, filter, deodorize and polish the extracted oils.
  • vegetable oil which has already been subjected to one or more of these refining processes can be used as the extractant.
  • the oils can be used directly as a feed or food additive to produce products enriched in CLA and other beneficial unsaturated fatty acids.
  • the oil can be further processed and purified as outlined below and then used in the above applications and also in pharmaceutical applications.
  • the lipids from the obtained milk products may be extracted by use of a solvent or mixture of solvents such as hexane, chloroform, ether, or methanol.
  • the solvent is removed (for example by a vacuum rotary evaporator, which allows the solvent to be recovered and reused) and the resulting lipid fraction can be hydro lyzed by using any of the well-known methods for converting triglycerides to free fatty acids or esters of fatty acids including base hydrolysis, acid hydrolysis, or enzymatic hydrolysis.
  • the hydrolysis is preferably carried out at as low a temperature as possible (e.g., room temperature to 60°C) and under nitrogen to minimize degradation of the unsaturated fatty acids.
  • nonsaponifiable compounds can be extracted into a solvent such as ether, hexane or chloroform and removed.
  • the remaining solution is then acidified by addition of an acid such as HCl and the free fatty acids can be extracted into a solvent such as hexane, ether, or chloroform.
  • the solvent solution containing the free fatty acids could then be cooled to a temperature low enough for the non-HUFAs to crystallize, but not so low that HUFAs crystallize.
  • the solution may be cooled to between about -60°C and about -74°C.
  • the crystallized fatty acids (saturated fatty acids, and mono-, di-, and tri-enoic fatty acids) can then be removed (while keeping the solution cooled) by filtration, centrifugation or settling.
  • the HUFAs remain typically dissolved in the filtrate (or supernatant).
  • the solvent in the filtrate (or supernatant) can then be removed leaving a mixture of fatty acids which are > 90% purity in either omega-3 HUFAs or HUFAs which are greater than or equal to 20 carbons in length.
  • the purified highly unsaturated fatty acids can then be used as a nutritional supplement for humans, as a food additive, or for pharmaceutical applications. For these uses the purified fatty acids can be encapsulated or used directly. Antioxidants are typically added to the fatty acids to improve their stability.
  • the milk product (or a dry form thereof) can be used directly as a food additive to enhance the content of CLA and other beneficial unsaturated fatty acids of processed foods for human intake or for animal feed.
  • CLA and other beneficial unsaturated fatty acids from the present dairy products may be incorporated into the flesh or other products of animals.
  • the complex lipids containing CLA and other beneficial unsaturated fatty acids can also be extracted from the milk product with solvents and utilized in a more concentrated form (e.g., encapsulated) for pharmaceutical or nutritional purposes and industrial applications.
  • a further aspect of the present invention includes introducing CLA and other beneficial unsaturated fatty acids from the foregoing sources into humans for the treatment of various diseases.
  • treat means both the remedial and preventative practice of medicine.
  • the dietary value of CLA and other beneficial unsaturated fatty acids is recognized in the literature as decribed herein, and intake of CLA and other beneficial unsaturated fatty acids produced in accordance with the present invention by humans can be effective for treating cardiovascular diseases, inflammatory and/or immunological diseases and cancer.
  • Separating milk fat into fractions that vary in melting properties can add value to the milk fat.
  • fractions are combined with custom blending and texturization technologies, a range of milk fat fraction ingredients with varying functional properties can be produced.
  • the most common method used to fractionate milk fat is dry crystallization, a simple, physical process that separates milk fat into fractions with different physical and chemical properties.
  • the process involves heating anhydrous milk fat (99.9%) fat) in a crystallizer (e.g., a stainless steel jacketed tank) until fully melted.
  • the milk fat is then allowed to cool and stirred using controlled conditions until the crystallization process is complete.
  • the result is a slurry consisting of solid milk fat crystals suspended in liquid milk fat.
  • the fractions may be separated — either by vacuum or pressure filtration or centrifugation ⁇ into milk fat ingredients with melting points much lower and higher than milk fat's typical melting point. Fractions with melting points ranging from 43-155°F may be obtained in this manner in contrast to the 95-96°F melting point of ordinary butter. While this type of process can change the physical characteristics of butter, it generally does not alter its characteristic flavor.
  • Milk fat fractions can be used to improve the texture of low-fat cheese and increase the spreadability of butter at refrigerated temperatures.
  • the functionality of cold-spreadable butter is a direct result of the functionality of the milk fat ingredients used.
  • the physical characteristics result from the complex interactions between the various phases (solid milk fat, liquid milk fat and aqueous).
  • One approach for making cold-spreadable butter is to add low-melting fractions to cream during the conventional butter churning process.
  • Another approach is to selectively blend milk fat fractions to achieve a desired melting profile, followed by emulsification with other ingredients and appropriate texturization.
  • a ratio of one-part high-melting fraction to three-part low-melting fraction has proved successful at the pilot level.
  • High-melting fractions can also be used in ultra high temperature-recombined creams to help increase creaming stability during storage and in whipped creams to improve physical and stability properties.
  • Two Holstein dairy cows were fed a total mixed ration consisting of 50%> concentrate, 25%> alfalfa haylage (farm-grown), and 25%> corn silage (farm-grown) on a dry matter basis as a basal diet for one week to acclimate them to the ration beginning on day 1.
  • the concentrate contained (expressed as percent of dry matter): corn, 58.9; soybean meal (44%> CP), 32.6; dicalcium phosphate, 1.5; limestone, 1.75; sodium bicarbonate, 1.5; magnesium oxide, 0.5; trace mineral salt, 1.0; vitamin A, D, E premix (2,000,000 IU of vitamin A, 400,000 IU of vitamin D, 200 IU of vitamin E per pound), 0.2; vitamin E premix (20,000 IU per pound), 0.1.
  • the cows were housed in a free stall facility at the South Dakota State University Dairy Research and Teaching Facility. The cows were fed using Calan feeding doors (American Calan, Inc., Northwood, NH) and amounts fed and refused were recorded daily.
  • Menhaden fish oil (Zapata Protein, Inc., Reedville, VA) was incorporated in the ration gradually beginning on day 9 until cows were offered 454 g offish oil daily. Fish oil was incorporated in the ration through day 29. Milk production, milk composition, feed intake, and milk fat composition were monitored through 4 weeks. Milk fat composition of samples from the cows fed fish oil was analyzed by * packed column gas chromatography (Jones, et al. Quantitative determination of double bond positions in unsaturated fatty acids after oxidative cleavage, J. Amer. Oil Chem. Soc, 42:121 (1965)). Ten ml of each milk sample were placed in individual Mojonnier flasks (Mojonnier, Charleston, SC).
  • An indicator 1.5 ml of ammonium hydroxide, 10 ml ethanol, 25 ml ethyl ether, and 25 ml of petroleum ether were added to the milk sample followed by centrifugation for one minute. The clear layer was decanted to a flask and the sample was evaporated to dryness on a rotary evaporator. Petroleum ether (approx 3 ml) was added to the flask and the sample was evaporated to dryness again. Boron trifluoride butanol (approximately 3 ml) was added to the sample and the sample was heated for approximately 30 minutes. Samples were allowed to cool while connected to a cold water condensor. Contents of the flask were then transferred to a separatory funnel.
  • a sample offish oil was analyzed by capillary column gas chromatography using the following procedure.
  • a 6 - 20 mg sample of fish oil was added to a 16 X 150 mm extraction tube, followed by 50 ml of a solution of 0.5%> valeric acid and 1.0%) 10-undecanoic acid in n-butanol as an internal standard.
  • n-Butanol 750 ml was added to the sample and vortexed for 4 - 5 seconds. While vortexing, 75 ml of acetyl chloride were slowly added to the sample. Samples were gassed with N 2 , sealed, and heated at 100° C for 1.5 h.
  • Results Table 2 shows the average milk production and composition of milk from the cows fed 454 g of fish oil daily for 14 days. Milk samples were obtained prior to beginning fish oil supplementation for the pretreatment values. Fish oil in the ration was increased gradually for 1 week, then cows were fed at 454 g of fish oil daily through week 1 and week 2. Milk samples were obtained at the end of week 1 and week 2.
  • Tank milk from the South Dakota State University Dairy Farm was used as a comparison for pretreatment and treatment milk samples.
  • the tank milk was from a herd of cows fed a diet containing the ingredients listed in Table 3.
  • Pretreatment milk samples were obtained from the cows to be fed the fish oil supplemented diet prior to initiation of daily supplementation with 454 gm of Menhaden fish oil.
  • Treatment milk samples were obtained after cows had been receiving 454 gm of Menhaden fish oil daily for 14 days. Samples were analyzed using a butyl esterification method of gas chromatography using a Varian model 3700.
  • Table 4 shows the fatty acid compositions (mg/g of fat) of the tank milk and milk produced by cows before and after supplementation of their feed with 454 gm (1.0 lb) by dry weight fish oil per cow.
  • Table 3 Contents of Basic Diet Fed to Herd From Which Tank Milk Obtained
  • Vitamin E premix 2 0.10
  • ⁇ Contains 2,000,000 IU of vitamin A, 400,000 IU of vitamin D, and 200 IU of vitamin E per pound.
  • Menhaden fish oil in diets fed to dairy cows provided long-chain fatty acids that resulted in alterations in milk fat composition.
  • percent of saturated fatty acids decreased from approximately 71% pretreatment to 61%> during treatment with a concurrent increase in unsaturated fatty acids from approximately 27%> to 36%>.
  • Saturated fats have been implicated as a risk factor in generation of heart disease, therefore health care officials have recommended a shift from saturated fatty acids to unsaturated fatty acids. Feeding fish oil to dairy cows results in decreased percentages of saturated fatty acids in milk fat thereby providing a healthier product for human consumption.
  • Average pretreatment values (see Table 4) for CLA were 3.1 mg/g of fat compared to 27.2 mg CLA g of fat in samples from cows fed the fish oil supplemented diet.
  • the increase in CLA varied between animals from 23 mg/g of fat to 31.3 mg/g of fat.
  • Soybean meal 44% CP 20.0 200.0
  • Milk samples (a.m. and p.m.) were composited for analysis of milk composition (fat %>, protein %>, lactose %>, solids, and somatic cell count) and milk fat composition by gas chromatography. Milk weights are recorded for each milking. Milk samples were obtained on day 3 prior to initiation of feeding fish oil, on days 7 and 10 after starting incorporation offish oil (fish meal), and on day 14 after cows were receiving full allotments of fish oil (fish meal). Samples were analyzed for fatty acid composition using a butyl esterification method by gas chromatography (Hewlett-Packard model 6890). The results are shown in Tables 7- 9.
  • Fatty acid composition (mg/g of fat) of tank milk, pretreatment milk, and posttreatment milk
  • Fatty acid composition (mg/g of fat) of milk from cows fed fish oil
  • Dry matter intake is the average daily intake for day 1 through 3 (Pre), day 4 through 9 (Step-up), and day 10 through 16 (Full).
  • Fish Oil Intake is the average daily intake for day 10 through 16 (Full).

Landscapes

  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Dairy Products (AREA)

Abstract

L'invention concerne un produit laitier enrichi en acides linoléiques conjugués ('CLA') et/ou en d'autres acides gras insaturés utiles. En règle générale, le produit laitier comporte une fraction de matières grasses avec une composition d'acides gras qui comprend au moins 15 mg/g de CLA ainsi que, de préférence, au moins 10 mg/g d'un acide gras oméga-3. On fabrique le produit laitier à l'aide d'un ruminant qui a été nourri selon un régime comportant un produit dérivé du poisson tel que l'huile de poisson ou la farine de poisson. D'ordinaire, ce régime comprend entre environ 0,5 % et environ 5,0 % en poids sec d'huile de poisson provenant du produit dérivé du poisson. Parmi les exemples de produits laitiers de cette invention, on peut citer le lait, cru ou transformé, ainsi que d'autres produits dérivés du lait. L'invention concerne également des fractions lipidiques isolées et des compositions d'acides gras qui sont dérivées du lait cru.
PCT/US1998/016829 1997-08-18 1998-08-13 Produits laitiers a teneur elevee en acides linoleiques conjugues WO1999008540A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NZ503398A NZ503398A (en) 1997-08-18 1998-08-13 Dairy products with enhanced conjugated linoleic acid content derived from milk of ruminants fed with fish oil
AU88287/98A AU728842B2 (en) 1997-08-18 1998-08-13 Dairy products with enhanced CLA content
EP98939938A EP1005277A4 (fr) 1997-08-18 1998-08-13 Produits laitiers a teneur elevee en acides linoleiques conjugues

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5567597P 1997-08-18 1997-08-18
US60/055,675 1997-08-18
US99244097A 1997-12-17 1997-12-17
US08/992,440 1997-12-17

Publications (1)

Publication Number Publication Date
WO1999008540A1 true WO1999008540A1 (fr) 1999-02-25

Family

ID=26734514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016829 WO1999008540A1 (fr) 1997-08-18 1998-08-13 Produits laitiers a teneur elevee en acides linoleiques conjugues

Country Status (4)

Country Link
EP (1) EP1005277A4 (fr)
AU (1) AU728842B2 (fr)
NZ (1) NZ503398A (fr)
WO (1) WO1999008540A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956400A1 (de) * 1999-11-24 2001-06-13 Angelos Sagredos Therapeutisch wirksame Zusammensetzung, ein Verfahren zu ihrer Herstellung und ihre Verwendung
WO2001085161A1 (fr) * 2000-05-05 2001-11-15 Fresenius Kabi Deutschland Gmbh Preparation combinant des acides gras φ-3 et des acides linoleniques conjugues pour le traitement de maladies caracterisees par des tableaux cliniques a composante immunologique marquee
WO2002051255A1 (fr) 2000-12-22 2002-07-04 Universite Catholique De Louvain Procede de modification du profile isomerique d'acides gras trans dans la viande et le lait de ruminants et d'augmentation de la concentration d'acides linoleiques conjugues (cla) cis-9, trans-11
WO2002070014A1 (fr) * 2001-03-07 2002-09-12 Natural Asa Compositions comprenant une emulsion aqueuse contenant un acide linoleique conjugue
WO2006063444A1 (fr) 2004-12-15 2006-06-22 O & T Farms Preparation et utilisation d'aliments pour animaux a haute teneur en omega-3 et omega-6
US9272009B2 (en) 2007-10-15 2016-03-01 Jbs United, Inc. Method for increasing performance of offspring
CN108064950A (zh) * 2016-11-15 2018-05-25 内蒙古伊利实业集团股份有限公司 一种具有保护心血管功效的液态乳制品及其制备方法
WO2018109203A3 (fr) * 2016-12-15 2018-08-09 Frieslandcampina Nederland B.V. Fractionnement bidimensionnel de matière grasse de lait

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110292113A (zh) * 2018-03-21 2019-10-01 味全食品工业股份有限公司 反刍动物分泌的乳汁及乳制品

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770247A (en) * 1996-10-03 1998-06-23 Wisconsin Alumni Research Foundation Method of increasing the CLA content of cow's milK

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770247A (en) * 1996-10-03 1998-06-23 Wisconsin Alumni Research Foundation Method of increasing the CLA content of cow's milK

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1005277A4 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956400A1 (de) * 1999-11-24 2001-06-13 Angelos Sagredos Therapeutisch wirksame Zusammensetzung, ein Verfahren zu ihrer Herstellung und ihre Verwendung
DE19956400B4 (de) * 1999-11-24 2005-09-08 Sagredos, Angelos, Prof. Dr. Therapeutisch wirksame Zusammensetzung, ein Verfahren zu ihrer Herstellung und ihre Verwendung
WO2001085161A1 (fr) * 2000-05-05 2001-11-15 Fresenius Kabi Deutschland Gmbh Preparation combinant des acides gras φ-3 et des acides linoleniques conjugues pour le traitement de maladies caracterisees par des tableaux cliniques a composante immunologique marquee
WO2002051255A1 (fr) 2000-12-22 2002-07-04 Universite Catholique De Louvain Procede de modification du profile isomerique d'acides gras trans dans la viande et le lait de ruminants et d'augmentation de la concentration d'acides linoleiques conjugues (cla) cis-9, trans-11
WO2002070014A1 (fr) * 2001-03-07 2002-09-12 Natural Asa Compositions comprenant une emulsion aqueuse contenant un acide linoleique conjugue
US8349894B2 (en) 2001-03-07 2013-01-08 Aker Biomarine Asa Compositions comprising an o/w emulsion containing conjugated linoleic acid
WO2006063444A1 (fr) 2004-12-15 2006-06-22 O & T Farms Preparation et utilisation d'aliments pour animaux a haute teneur en omega-3 et omega-6
US10583159B2 (en) 2007-04-20 2020-03-10 United Animal Health, Inc. Method for increasing performance of offspring
US9272009B2 (en) 2007-10-15 2016-03-01 Jbs United, Inc. Method for increasing performance of offspring
US9675651B2 (en) 2007-10-15 2017-06-13 Jbs United, Inc. Method for increasing performance of offspring
CN108064950A (zh) * 2016-11-15 2018-05-25 内蒙古伊利实业集团股份有限公司 一种具有保护心血管功效的液态乳制品及其制备方法
WO2018109203A3 (fr) * 2016-12-15 2018-08-09 Frieslandcampina Nederland B.V. Fractionnement bidimensionnel de matière grasse de lait

Also Published As

Publication number Publication date
AU728842B2 (en) 2001-01-18
EP1005277A1 (fr) 2000-06-07
EP1005277A4 (fr) 2001-08-29
NZ503398A (en) 2002-06-28
AU8828798A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
Bauman et al. Production of butter with enhanced conjugated linoleic acid for use in biomedical studies with animal models
AbuGhazaleh et al. Conjugated linoleic acid and vaccenic acid in rumen, plasma, and milk of cows fed fish oil and fats differing in saturation of 18 carbon fatty acids
Chilliard et al. A review of nutritional and physiological factors affecting goat milk lipid synthesis and lipolysis
AU2001273028B2 (en) Improved methods of incorporating polyunsaturated fatty acids in milk
KR100619651B1 (ko) 공액 리놀레산 조성물
Abu-Ghazaleh et al. Conjugated linoleic acid and other beneficial fatty acids in milk fat from cows fed soybean meal, fish meal, or both
La Terra et al. Increasing pasture intakes enhances polyunsaturated fatty acids and lipophilic antioxidants in plasma and milk of dairy cows fed total mix ration
Enjalbert et al. Effects of duodenal infusions of palmitic, stearic, or oleic acids on milk composition and physical properties of butter
US20030175403A1 (en) Potentiated bioactive additives and method of use
AU2001273028A1 (en) Improved methods of incorporating polyunsaturated fatty acids in milk
Djordjevic et al. Fatty acid profile of milk
Nudda et al. Relationships between the contents of vaccenic acid, CLA and n− 3 fatty acids of goat milk and the muscle of their suckling kids
Santurino et al. Characterization of naturally goat cheese enriched in conjugated linoleic acid and omega-3 fatty acids for human clinical trial in overweight and obese subjects
JP3614859B2 (ja) ネルボン酸組成物
AU728842B2 (en) Dairy products with enhanced CLA content
Moallem et al. Transfer rate of α-linolenic acid from abomasally infused flaxseed oil into milk fat and the effects on milk fatty acid composition in dairy cows
Sharma et al. Role of omega-3 fatty acids, conjugated linoleic acid and phytosterols in improving functionality of dairy products
Kraft et al. Duodenal infusion of conjugated linoleic acid mixture influences milk fat synthesis and milk CLA content in dairy cows
Özyürek et al. Fatty acid profile and health lipid indices in the milk of ewes feeding with soybean oil
Abbas et al. MILK BIOACTIVE LIPIDS AS POTENTIAL HEALTHY FRACTIONS: A REVIEW
Nudda et al. The use linseed and cottonseed to change the milk fatty acid profile in early lactation dairy goats
Gunstone Why are structured lipids and new lipids sources required
WO2005036981A1 (fr) Procede pour enrichir l'acide nervonique contenu dans le lait tire de ruminants
Sharma et al. Fatty Acids, Triacylglycerols, and Phospholipids
CA3129557A1 (fr) Lait bovin dote d'une teneur elevee en acide gras n6-polyinsature

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 88287/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998939938

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 503398

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1998939938

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998939938

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 88287/98

Country of ref document: AU